Fig. 2From: Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose studyEffect of patisiran on wild-type and mutant TTR in patients with the Val30Met mutation. a All post-dose data. b Patisiran 300 mg/kg groups (error bars represent SEM). Q3W: every 3 weeks; Q4W: every 4 weeks; SEM: standard error of the mean; TTR: transthyretin; wt: wild-typeBack to article page